Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4827945 | 0.99 | UTS2R (0.49) | UTS2RROCK2ROCK1CCR5KMT2A | |
| SCHEMBL4828145 | 0.92 | GAA (0.46) | UTS2RROCK2ROCK1CCR5KMT2A | |
| Hydrochloric Acid SCHEMBL4830837 | 0.91 | GAA (0.46) | UTS2RROCK2ROCK1CCR5KMT2A | |
| SCHEMBL4836932 | 0.90 | KMT2A (0.43) | UTS2RCCR5KMT2AHDAC6LMNA | |
| Hydrochloric Acid SCHEMBL4836642 | 0.90 | KMT2A (0.42) | UTS2RCCR5KMT2AHDAC6LMNA | |
| SCHEMBL4828107 | 0.89 | HDAC6 (0.48) | UTS2RROCK2ROCK1CCR5KMT2A | |
| SCHEMBL4833330 | 0.89 | CCR5 (0.43) | UTS2RCCR5KMT2AHDAC6LMNA | |
| SCHEMBL4833322 | 0.89 | CCR5 (0.43) | UTS2RCCR5KMT2AHDAC6LMNA | |
| SCHEMBL4830969 | 0.89 | KMT2A (0.41) | UTS2RCCR5KMT2AHDAC6LMNA | |
| SCHEMBL4830960 | 0.89 | LMNA (0.44) | UTS2RCCR5KMT2AHDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | claimed |
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-04-07 | — | — | US | claimed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
| US-7351713-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075360-A1 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | UTS2R 118/4885ROCK2 3321/4885ROCK1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.